Navigation Links
MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development

SCOTTSDALE, Ariz., Jan. 23 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published two new reports providing critical strategic insight for companies developing therapies to treat hematologic malignancies. These reports are based on primary interviews conducted with hematology experts from North America immediately following the American Society of Hematology (ASH) annual meeting.

The first report, entitled "Thought Leader Insight & Analysis - AML/MDS," focuses on acute myelogenous leukemia and myelodysplastic syndrome. "This report highlights the most important data presented at ASH, and clarifies the ways these data will change clinical practice," according to Jeff Berk, MedPredict president. "A key emphasis of this report is transplant, and how pharmaceuticals and biologicals better prepare patients for transplant. Our thought leader panel discusses how to achieve complete responses, how they are thinking about combination therapy, and new ways for attacking quiescent malignant stem cells."

The second report, entitled "Thought Leader Insight & Analysis - Multiple Myeloma/Lymphoma," focuses on how the clinical data presented at ASH is likely to translate into changing treatment paradigms. "This report brings together the diverse perspectives of experts who grapple with a wide spectrum of issues related to these hematologic malignancies, including clinical pathology, community based patients, tertiary care treatment, and medical oncology from the strategic vantage point of clinical commercial development," said Berk.

Topics this report addresses include:

    -- Reimbursement: oral vs. parenteral; induction vs. maintenance.

    -- Multiple myeloma/lymphoma treatment strategies, including:

         - transplant eligible/non-transplant eligible;
         - induction/maintenance;
         - doublets/triplets;
         - community/tertiary care;
         - +65 years old/younger; and
         - approval pathways.

Companies mentioned in these reports include: Allos, Amgen, Bayer-Schering, Biogen Idec, BMS (Kosan), Celgene, Cell Therapeutics, Cephalon, Eisai, Genentech, Genmab, Genzyme, Geron, GSK, Gloucester, ImmunoGen, Incyte, Keryx, Mayo Scottsdale, Merck, Nereus, Novartis, PDL Biopharma, Proteolix, Rigel, Roche, Seattle Genetics, Takeda/Millennium, Vion, Wyeth, Xencor.

This report can be purchased by contacting MedPredict (

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiovascular Meds May Be Beneficial in Alzheimers Disease, According to MedPredict Report
2. Media Alert: PricewaterhouseCoopers Publishes Brief on the Impact of Government Health Reform on U.S. Employers
3. Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008
4. Zebrafish Journal Publishes Skin Pigmentation Studies That Shed Light on the Evolution of Race
5. Publishes Health Insurance Guide for the Recently Unemployed
6. Dynamics Group AG Publishes Research Report on Senetek
7. Publishes Safe Strategies for Drug Savings to Help All Americans Get Affordable Medication
8. AMA Journal Publishes Study Showing Evidence of a Major Environmental Trigger For Autism
9. (Report) World Privacy Forum Publishes Red Flag Rule Suggestions for Hospitals and Providers; New FTC-Enforced Rules Go Into Effect Nov. 1, Can Apply to Health Care Providers
10. Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome
11. The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008
Post Your Comments:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: